Abstract:Background: The concept of individualized therapy has advanced the development of prognostic biomarkers to manage patients with breast cancer (BRCA). Immunotherapy has shown great potential in treating BRCA, and the C-X-C motif chemokine receptor (CXCR) has generated interest in regulating tumor progression through the immune microenvironment. Although CXCRs were utilized for prognosis prediction in glioma with favourable capability, the prognostic and therapeutic role of CXCR in BRCA is unclear. Methods: We used The Cancer Genome Atlas (TCGA) database to analyze 1,095 BRCA patients' transcription, mutation, survival time and survival status. Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE), Cell-type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT), quanTIseq, and Estimating the Proportion of Immune and Cancer cells (EPIC) algorithms were performed to infer the association of CXCR genes with immune cells. We randomly divided the TCGA dataset into a training set and a validation set according to 1:1, constructed a LASSO Cox regression model based on CXCR family genes using the glmnet R package in the training set, assembled clinical variables to draw a visual Nomogram using the R package rms, and validated the model by receiver operating characteristic (ROC) curves, calibration curves with clinical decision curves in the validation set efficacy. Results: Compared to normal samples, CXCR3/4/5 messenger RNA (mRNA) expression levels were upregulated in BRCA samples, whereas CXCR1/2 mRNA expression levels were downregulated. High CXCR3/5/6 expression was associated with a good prognosis. Subsequently, we divided the CXCRs into 2 molecular subgroups based on their expression patterns and explored prognosis, immune infiltration, functional enrichment, hallmarks, and immune response differentiation between the two subgroups. After LASSO Cox regression modeling, a CXCR score predicting overall survival (OS) was constructed, and the predictive accuracy was assessed. By pooling clinical variables, a nomogram individual risk assessment method was established to measure the identification of genuinely high-risk patients who should receive interventions. Conclusions: In summary, CXCR genes were associated with immune infiltration and survival in BRCA patients, and our CXCR-based prognostic model could better predict the prognosis of BRCA patients and provide potential immunotherapy targets for clinical purposes.

The Role and Clinical Significance of the CXCL17-CXCR8 (GPR35) Axis in Breast Cancer

Prognostic Value of CXCL17 and CXCR8 Expression in Patients with Colon Cancer.

Expression and clinical significance of CXCL17 and GPR35 in endometrial carcinoma

Complicated Prognostic Values of CCL28 in Breast Cancer by Subtype

CXCL8 in Tumor Biology and Its Implications for Clinical Translation

Prognostic and Clinicopathological Significance of CXCL1 Expression in Gastric Cancer: A Meta-Analysis.

CXCL8 Associated Dendritic Cell Activation Marker Expression and Recruitment as Indicators of Favorable Outcomes in Colorectal Cancer

Involvement of CXCL17 and GPR35 in Gastric Cancer Initiation and Progression

Prognostic Significance and Therapeutic Target of CXC Chemokines in the Microenvironment of Lung Adenocarcinoma

Analysis of C-X-C motif chemokine receptors in breast cancer: potential value in immunotherapy and prognostic prediction

The Clinical and Prognostic Value of CXCL8 in Cervical Carcinoma Patients: Immunohistochemical Analysis.

Expression of Chemokine Receptor CXCR7 in Colorectal Carcinoma and Its Prognostic Significance.

CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target

170P Clinical Significance and Functional Role of GPR56 (ADGRG1) in Breast Cancer

The Role of CXCR3 and Its Ligands in Cancer

CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis

Identification of Potential Therapeutic Targets among CXC Chemokines in Breast Tumor Microenvironment Using Integrative Bioinformatics Analysis

Prognostic Value and Therapeutic Significance of CCL Chemokines in Gastric Cancer

Chemokine (C-X-C Motif) Ligand 1 is Associated with Tumor Progression and Poor Prognosis in Patients with Colorectal Cancer

An inter-correlation among chemokine (C-X-C motif) ligand (CXCL) 1, CXCL2 and CXCL8, and their diversified potential as biomarkers for tumor features and survival profiles in non-small cell lung cancer patients

Positive expression of chemokine (C-C Motif) ligand 18 and prognosis in cancer: A meta-analysis.